Evidence map›Paper›PMID 36010953›Full record

ArticleCancers2022

Characteristics, Treatments, and Survival of Uveal Melanoma: A Comparison between Chinese and American Cohorts.

Jingting Luo, Chengkai Zhang, Yuhang Yang, Jingying Xiu, Hanqing Zhao, Chuqiao Liang, Zhaoxun Feng, Yuning Chen, Yueming Liu, Yang Li and 1 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingting LuoBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Chengkai ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100730, China.
Yuhang YangBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Jingying XiuBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Hanqing ZhaoBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Chuqiao LiangBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.ORCID 0000-0003-4733-7957
Zhaoxun FengDepartment of Ophthalmology, University of Ottawa, 501 Smyth Rd, Ottawa, ON K1H 8M2, Canada.
Yuning ChenBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Yueming LiuBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Yang LiBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.
Wenbin WeiBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing 100730, China.

Funding

Beijing Dongcheng District Outstanding Talents Cultivating Plan 2018Beijing Municipal Administration of Hospitals' Youth Programme QMS20190203Beijing Natural Science Foundation 7204245National Natural Science Foundation of China 82101180National Natural Science Foundation of China 82141128Science & Technology Project of Beijing Municipal Science & Technology Commission Z181100001818003Science & Technology Project of Beijing Municipal Science & Technology Commission Z201100005520045Scientific Research Common Program of Beijing Municipal Commission of Education, grant number KM202010025018The Capital Health Research and Development of Special 2020-1-2052
6 · The paper itself

Abstract

Uveal melanoma (UM) is the most common intraocular malignant carcinoma. This study aimed to compare the clinical features, treatment modalities, and prognosis of UM patients in China with those in America over a 15-year period. In the study, 4088 American patients with primary UM from the Surveillance, Epidemiology, and End Results (SEER) database and 1508 Chinese patients from Tongren-ophthalmology Research Association of Clinical Evaluation (TRACE) were included. Univariable and multivariable analyses were performed to determine prognostic factors and propensity score matching (PSM) and sensitivity analyses were applied to adjust for confounders and identify independent prognostic factors. Chinese patients were diagnosed at a younger age (mean ± SD, 47.3 ± 12.5 years vs. 59.7 ± 14.8 years) and tumors at diagnosis were larger (diameter: 12.0 ± 3.54 mm vs. 11.3 ± 8.27 mm; thickness: 7.13 ± 3.28 mm vs. 4.91 ± 3.01 mm). Chinese patients were more likely to undergo brachytherapy than American patients. Chinese patients had better overall survival than American patients while no significant differences exhibited after adjusting for age through PSM. In conclusion, compared with American patients, Chinese patients had younger onset age, larger tumors at diagnosis and better prognosis, mainly because of their younger age.

Indexed as

AmericancharacteristicsChinesesurvivaltreatmentsuveal melanoma

Identifiers

PMID36010953
PMCPMC9406112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.